Viralytics’ Cavatak continues to impress, with a 100% disease control rate in 10 patients (seven objective responses) in combination with Keytruda in the CAPRA Phase Ib study. Furthermore, in the MITCI Phase Ib trial Cavatak, in combination with Yervoy, achieved a 50% response rate in the first 18 patients treated, which is an impressive response rate in a heavily pre-treated population. The encouraging results are a good sign for the ongoing trials of Cavatak and are likely to be of gr
21 Nov 2016
Cavatak data continue to impress
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cavatak data continue to impress
Viralytics (VLA:ASX) | 0 0 -4.6% | Mkt Cap: 175.3m
- Published:
21 Nov 2016 -
Author:
Dr Dennis Hulme -
Pages:
8
Viralytics’ Cavatak continues to impress, with a 100% disease control rate in 10 patients (seven objective responses) in combination with Keytruda in the CAPRA Phase Ib study. Furthermore, in the MITCI Phase Ib trial Cavatak, in combination with Yervoy, achieved a 50% response rate in the first 18 patients treated, which is an impressive response rate in a heavily pre-treated population. The encouraging results are a good sign for the ongoing trials of Cavatak and are likely to be of gr